Formycon AG
FYB
Rank in Stocks
#15003
Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly... Headquartered in Planegg, Germany, Formycon AG, founded in 1999 and formerly known as Nanohale AG until 2012, specializes in the development and commercialization of biosimilar medications. Its robust product pipeline includes FYB201, a biosimilar equivalent to Lucentis, which is intended for the treatment of neovascular age-related macular degeneration and other severe eye conditions. The company is also progressing with FYB202, a biosimilar of Stelara, currently undergoing Phase III clinical trials for various inflammatory diseases, including moderate to severe psoriasis, Crohn's disease, and ulcerative colitis. Additionally, FYB203, a biosimilar candidate for Eylea, is in Phase III clinical trials, aiming to address similar ocular diseases like neovascular age-related macular degeneration. Further endeavors include the development of FYB206 and FYB207, with the latter being an antiviral treatment for COVID-19. To ensure the stability of its numerous drug candidates, Formycon AG maintains a collaborative agreement with Leukocare AG.
Share Price
$16.27
Last synced: 2026-11-09
Market Cap
$287.59M
Change (1 day)
3.53%
Change (1 year)
-34.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Formycon AG (FYB)
Category
Healthcare
Operating Margin for Formycon AG (FYB)
Operating Margin as of November 2026 TTM: -25.51%
According to Formycon AG's latest financial reports, its current operating margin (TTM) is -25.51%. At the end of 2025 the company had an operating margin of -66.03%.
Operating Margin history for Formycon AG from 2009 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -25.51% | -61.37% |
| 2025 | -66.03% | 95.41% |
| 2024 | -33.79% | 7,089.36% |
| 2023 | -0.47% | -98.87% |
| 2022 | -41.72% | 10.46% |
| 2021 | -37.77% | 97.65% |
| 2020 | -19.11% | 178.98% |
| 2019 | -6.85% | -141.36% |
| 2018 | 16.56% | -406.10% |
| 2017 | -5.41% | -73.86% |
| 2016 | -20.70% | -626.72% |
| 2015 | 3.93% | -43.21% |
| 2014 | 6.92% | -100.25% |
| 2013 | -2,801.46% | 68.90% |
| 2012 | -1,658.69% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | -2,070.16% | 116.77% |
| 2009 | -955.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.51% |
US
|
|
| -149.01% | -94.16% |
US
|
|
| 25.57% | -101.00% |
AU
|
|
| 31.23% | -101.22% |
BE
|
|
| 29.35% | -101.15% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Formycon AG's operating margin
What is Formycon AG's operating margin?
Formycon AG's operating margin is -25.51%, as of Nov 2026.
What was Formycon AG's operating margin in 2025?
In 2025, Formycon AG's operating margin was -66.03%, compared with -33.79% in 2024.
How has Formycon AG's operating margin changed since 2020?
From 2020 to 2025, Formycon AG's operating margin was highest in 2023 (-0.47%) and lowest in 2025 (-66.03%).
How does Formycon AG's operating margin compare with similar companies?
Formycon AG's operating margin (-25.51%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.